Kite, Daiichi Sankyo Change YESCARTA® CAR T-Cell Therapy Licensing Agreement in Japan

  Daiichi Sankyo to Transfer Yescarta Marketing Authorization in Japan to Gilead Sciences K.K. –

– Kite Cell Therapy Business Unit at Gilead Sciences K.K. Will Manage the Sales and Promotion Activities in Japan After the Marketing Authorization Transfer –

https://finance.yahoo.com/news/kite-daiichi-sankyo-announce-changes-213000059.html